Taplitumomab paptox

Drug Profile

Taplitumomab paptox

Alternative Names: B43 (anti-CD19) immunotoxin; B43-PAP; Monoclonal antibody B43-PAP conjugate

Latest Information Update: 29 Aug 2002

Price : $50

At a glance

  • Originator University of Minnesota
  • Class Antineoplastics; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Leukaemia

Most Recent Events

  • 29 Apr 1999 A phase I study has been added to the therapeutic trials and adverse events sections
  • 19 Jan 1999 Phase-III clinical trials for Leukaemia in USA (Unknown route)
  • 01 Sep 1998 Profile reviewed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top